High glucose inhibits the aspirin-induced activation of the nitric oxide/cGMP/cGMP-dependent protein kinase pathway and does not affect the aspirin-induced inhibition of thromboxane synthesis in human platelets

Diabetes

Volumn 61, Issue 11, 2012, Pages 2913-2921

  Russo, Isabella ^a   Viretto, Michela ^a   Barale, Cristina ^a   Mattiello, Luigi ^a   Doronzo, Gabriella ^a   Pagliarino, Andrea ^a   Cavalot, Franco ^a   Trovati, Mariella ^a   Anfossi, Giovanni ^a  

^a SAN LUIGI GONZAGA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE; ARACHIDONIC ACID; CYCLIC GMP; CYCLIC GMP DEPENDENT PROTEIN KINASE; GLUCOSE; LYSINE ACETYLSALICYLATE; MANNITOL; NITRIC OXIDE; THROMBOXANE;

ANTICOAGULATION; ARTICLE; DRUG MECHANISM; ENZYME ACTIVATION; FATTY ACID SYNTHESIS; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HYPERGLYCEMIA; NORMAL HUMAN; NUCLEOTIDE METABOLISM; PRIORITY JOURNAL; SHEAR STRENGTH; THROMBOCYTE; THROMBOCYTE AGGREGATION;

ADULT; AMIFOSTINE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; BLOOD PLATELETS; CELL ADHESION MOLECULES; CYCLIC GMP; CYCLIC GMP-DEPENDENT PROTEIN KINASES; DRUG RESISTANCE; FEMALE; HUMANS; HYPERGLYCEMIA; LYSINE; MALE; MICROFILAMENT PROTEINS; NITRIC OXIDE; PHOSPHOPROTEINS; PHOSPHORYLATION; PLATELET AGGREGATION INHIBITORS; PROTEIN PROCESSING, POST-TRANSLATIONAL; SECOND MESSENGER SYSTEMS; THROMBOXANES; VASODILATOR AGENTS; YOUNG ADULT;

EID: 84868007942     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db12-0040     Document Type: Article

References (44)

1. Stamler JM, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16:434-444
2. Davì G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med 2007;357:2482-2494
3. Vinik AI, Erbas T, Park TS, Nolan R, Pittenger GL. Platelet dysfunction in type 2 diabetes. Diabetes Care 2001;24:1476-1485
4. American Diabetes Association. Standards of medical care in diabetes - 2011. Diabetes Care 2011;34(Suppl. 1):S11-S61
5. Ajjan R, Storey RF, Grant PJ. Aspirin resistance and diabetes mellitus. Diabetologia 2008;51:385-390
6. Angiolillo DJ. Antiplatelet therapy in diabetes: efficacy and limitations of current treatment strategies and future directions. Diabetes Care 2009;32: 531-540
7. De Berardis G, Sacco M, Strippoli GF, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. BMJ 2009;339:b4531
8. Patrono C, Rocca B. Aspirin: promise and resistance in the new millennium. Arterioscler Thromb Vasc Biol 2008;28:s25-s32
9. Anfossi G, Russo I, Trovati M. Resistance to aspirin and thienopyridines in diabetes mellitus and metabolic syndrome. Curr Vasc Pharmacol 2008;6: 313-328
10. Sweeny JM, Gorog DA, Fuster V. Antiplatelet drug 'resistance'. Part 1: mechanisms and clinical measurements. Nat Rev Cardiol 2009;6:273-282
11. Anfossi G, Russo I, Trovati M. Platelet dysfunction in central obesity. Nutr Metab Cardiovasc Dis 2009;19:440-449
12. Santilli F, Vazzana N, Liani R, Guagnano MT, Davì G. Platelet activation in obesity and metabolic syndrome. Obes Rev 2012;13:27-42
13. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005;54:1615-1625
14. Watala C, Golanski J, Pluta J, et al. Reduced sensitivity of platelets from type 2 diabetic patients to acetylsalicylic acid (aspirin)-its relation to metabolic control. Thromb Res 2004;113:101-113
15. Watala C, Ulicna O, Golanski J, et al. High glucose contributes to aspirin insensitivity in streptozotocin-diabetic rats: a multiparametric aggregation study. Blood Coagul Fibrinolysis 2006;17:113-124
16. Cohen HW, Crandall JP, Hailpern SM, Billett HH. Aspirin resistance associated with HbA1c and obesity in diabetic patients. J Diabetes Complications 2008;22:224-228
17. De La Cruz JP, Arrebola MM, Villalobos MA, et al. Influence of glucose concentration on the effects of aspirin, ticlopidine and clopidogrel on platelet function and platelet-subendothelium interaction. Eur J Pharmacol 2004;484:19-27
18. Le Guyader A, Pacheco G, Seaver N, Davis-Gorman G, Copeland J, McDonagh PF. Inhibition of platelet GPIIb-IIIa and P-selectin expression by aspirin is impaired by stress hyperglycemia. J Diabetes Complications 2009;23:65-70
19. Kobzar G, Mardla V, Samel N. Short-term exposure of platelets to glucose impairs inhibition of platelet aggregation by cyclooxygenase inhibitors. Platelets 2011;22:338-344
20. Capes SE, Hunt D, Malmberg K, Gerstein HC. Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. Lancet 2000;355:773-778
21. Ceriello A, Colagiuri S. International Diabetes Federation guideline for management of postmeal glucose: a review of recommendations. Diabet Med 2008;25:1151-1156
22. Cavalot F, Pagliarino A, Valle M, et al. Postprandial blood glucose predicts cardiovascular events and all-cause mortality in type 2 diabetes in a 14-year follow-up: lessons from the San Luigi Gonzaga Diabetes Study. Diabetes Care 2011;34:2237-2243
23. Awtry EH, Loscalzo J. Aspirin. Circulation 2000;101:1206-1218
24. Patrono C, Coller B, Dalen JE, et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest 2001;119(Suppl.):39S-63S
25. O'Kane PD, Queen LR, Ji Y, et al. Aspirin modifies nitric oxide synthase activity in platelets: effects of acute versus chronic aspirin treatment. Cardiovasc Res 2003;59:152-159
26. Chakraborty K, Khan GA, Banerjee P, Ray U, Sinha AK. Inhibition of human blood platelet aggregation and the stimulation of nitric oxide synthesis by aspirin. Platelets 2003;14:421-427
27. Madajka M, Korda M, White J, Malinski T. Effect of aspirin on constitutive nitric oxide synthase and the biovailability of NO. Thromb Res 2003;110: 317-321
28. O'Kane P, Xie L, Liu Z, et al. Aspirin acetylates nitric oxide synthase type 3 in platelets thereby increasing its activity. Cardiovasc Res 2009;83:123-130
29. Gkaliagkousi E, Ritter J, Ferro A. Platelet-derived nitric oxide signaling and regulation. Circ Res 2007;101:654-662
30. Butt E, Abel K, Krieger M, Palm D, Hoppe V, Walter U. cAMP- and cGMP-dependent protein kinase in vitro and in intact human platelets. J Biol Chem 1994;269:14509-14517
31. Anfossi G, Mularoni EM, Burzacca S, et al. Platelet resistance to nitrates in obesity and obese NIDDM, and normal platelet sensitivity to both insulin and nitrates in lean NIDDM. Diabetes Care 1998;21:121-126
32. Majluf-Cruz A, Chavez-Ochoa AR, Majluf-Cruz K, et al Effect of combined administration of clopidogrel and lysine acetylsalicylate versus clopidogrel and aspirin on platelet aggregation and activated GPIIb/IIIa expression in healthy volunteers. Platelets 2006;17:105-107
33. Kobsar A, Koessler J, Kehrer L, Gambaryan S, Walter U. The thrombin inhibitors hirudin and Refludan(®) activate the soluble guanylyl cyclase and the cGMP pathway in washed human platelets. Thromb Haemost 2012; 107:521-529
34. Favaloro EJ. Clinical utility of the PFA-100. Semin Thromb Hemost 2008; 34:709-733
35. Born GVR. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962;194:927-929
36. Queen LR, Xu B, Horinouchi K, Fisher I, Ferro A. b(2)-adrenoceptors activate nitric oxide synthase in human platelets. Circ Res 2000;87:39-44
37. Russo I, Del Mese P, Doronzo G, et al Platelet resistance to the antiaggregatory cyclic nucleotides in central obesity involves reduced phosphorylation of vasodilator-stimulated phosphoprotein. Clin Chem 2007;53: 1053-1060
38. Gresele P, Marzotti S, Guglielmini G, et al. Hyperglycemia-induced platelet activation in type 2 diabetes is resistant to aspirin but not to a nitric oxide-donating agent. Diabetes Care 2010;33:1262-1268
39. Gresele P, Guglielmini G, De Angelis M, et al. Acute, short-term hyperglycemia enhances shear stress-induced platelet activation in patients with type II diabetes mellitus. J Am Coll Cardiol 2003;41:1013-1020
40. Russo I, Frascaroli C, Mattiello L, et al. Aspirin resistant subjects present a proinflammatory milieu with an increased oxidative stress: in these conditions, high glucose fails to influence platelet responses to agonists. Diabetologia 2011;54:S36 [Abstract]
41. Anfossi G, Russo I, Massucco P, Mattiello L, Trovati M. Platelet resistance to the antiaggregating effect of N-acetyl-L-cysteine in obese, insulin-resistant subjects. Thromb Res 2003;110:39-46
42. Marzatico F, Porta C, Moroni M, et al. In vitro antioxidant properties of amifostine (WR-2721, Ethyol). Cancer Chemother Pharmacol 2000;45:172-176
43. Massucco P, Mattiello L, Russo I, et al. High glucose rapidly activates the nitric oxide/cyclic nucleotide pathway in human platelets via an osmotic mechanism. Thromb Haemost 2005;93:517-526
44. Colwell JA, Nesto RW. The platelet in diabetes: focus on prevention of ischemic events. Diabetes Care 2003;26:2181-2188